

Bo R Rueda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2150274/publications.pdf>

Version: 2024-02-01

118
papers

6,522
citations

61857

43
h-index

69108

77
g-index

119
all docs

119
docs citations

119
times ranked

9234
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy. <i>Cancer Research</i> , 2022, 82, 773-784.	0.4	3
2	Abstract 3390: Preliminary results for a novel single extracellular vesicle assay for early stage ovarian cancer: The power of co-localized detection of surface biomarkers. <i>Cancer Research</i> , 2022, 82, 3390-3390.	0.4	0
3	Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development. <i>Oncogene</i> , 2022, 41, 3761-3777.	2.6	5
4	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 158-173.	0.4	85
5	Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. <i>Scientific Reports</i> , 2021, 11, 3718.	1.6	18
6	Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. <i>Cancers</i> , 2021, 13, 2195.	1.7	0
7	Transient commensal clonal interactions can drive tumor metastasis. <i>Nature Communications</i> , 2020, 11, 5799.	5.8	30
8	Reprogramming of ovarian granulosa cells by YAP1 leads to development of high-grade cancer with mesenchymal lineage and serous features. <i>Science Bulletin</i> , 2020, 65, 1281-1296.	4.3	8
9	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1206.	1.7	6
10	Galectins and Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1421.	1.7	18
11	CABLES1 Deficiency Impairs Quiescence and Stress Responses of Hematopoietic Stem Cells in Intrinsic and Extrinsic Manners. <i>Stem Cell Reports</i> , 2019, 13, 274-290.	2.3	5
12	The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 1678.	1.7	26
13	Understanding and Targeting Apoptotic Pathways in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1631.	1.7	22
14	A Human Papillomavirus-Independent Cervical Cancer Animal Model Reveals Unconventional Mechanisms of Cervical Carcinogenesis. <i>Cell Reports</i> , 2019, 26, 2636-2650.e5.	2.9	49
15	YAP1-LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis. <i>EMBO Reports</i> , 2019, 20, .	2.0	44
16	Ovarian cancer stem cells: What progress have we made?. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 107, 92-103.	1.2	41
17	PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2019, 17, 431-445.	1.5	40
18	Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau. <i>Oncotarget</i> , 2018, 9, 23289-23305.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma. PLoS ONE, 2018, 13, e0201314.	1.1	25
20	MicroRNA 21a-5p overexpression impacts mediators of extracellular matrix formation in uterine leiomyoma. Reproductive Biology and Endocrinology, 2018, 16, 46.	1.4	22
21	Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. MAbs, 2017, 9, 615-627.	2.6	45
22	Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecologic Oncology, 2017, 145, 446-452.	0.6	57
23	Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice. Oncotarget, 2017, 8, 7265-7275.	0.8	33
24	Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. Gynecologic Oncology, 2016, 141, 570-579.	0.6	3
25	Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. Journal of Ovarian Research, 2016, 9, 58.	1.3	22
26	MicroRNA-15b regulates reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in human uterine leiomyoma. Reproductive Biology and Endocrinology, 2016, 14, 45.	1.4	9
27	Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors. Cancer Biology and Therapy, 2016, 17, 262-271.	1.5	44
28	The Epidemiology and Genetics of Uterine Leiomyoma. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 34, 3-12.	1.4	75
29	The <i>Cables1</i> Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 513-522.	1.8	52
30	HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecologic Oncology, 2015, 137, 160-166.	0.6	29
31	The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist, 2015, 20, 1058-1068.	1.9	56
32	Characterization of extracellular DDX4- or Ddx4-positive ovarian cells. Nature Medicine, 2015, 21, 1114-1116.	15.2	41
33	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nature Communications, 2015, 6, 7419.	5.8	149
34	Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors. Cancer Letters, 2015, 356, 434-442.	3.2	45
35	Notch signaling in serous ovarian cancer. Journal of Ovarian Research, 2014, 7, 95.	1.3	71
36	The impact of vitrification on murine germinal vesicle oocyte In vitro maturation and aurora kinase A protein expression. Journal of Assisted Reproduction and Genetics, 2014, 31, 1695-1702.	1.2	4

#	ARTICLE	IF	CITATIONS
37	The Anti-inflammatory Impact of Omega-3 Polyunsaturated Fatty Acids During the Establishment of Endometriosis-Like Lesions. <i>American Journal of Reproductive Immunology</i> , 2014, 72, 392-402.	1.2	27
38	Dendritic Cells Attenuate the Early Establishment of Endometriosis-Like Lesions in a Murine Model. <i>Reproductive Sciences</i> , 2014, 21, 1228-1236.	1.1	33
39	Dual HER2 Targeting Impedes Growth of <i>HER2</i> Gene-Amplified Uterine Serous Carcinoma Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 6517-6528.	3.2	20
40	The N-methyl-D-aspartate Receptor, a Precursor to N-methyl-D-aspartate Receptor Encephalitis, is Found in the Squamous Tissue of Ovarian Teratomas. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 598-606.	0.9	15
41	Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth. <i>Frontiers in Oncology</i> , 2014, 4, 171.	1.3	34
42	Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartum. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 445.e1-445.e6.	0.7	28
43	Adrenomedullin is a therapeutic target in colorectal cancer. <i>International Journal of Cancer</i> , 2014, 134, 2041-2050.	2.3	22
44	MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?. <i>Human Reproduction Update</i> , 2014, 20, 670-687.	5.2	38
45	Evaluation of anastomotic strength and drug safety after short-term sunitinib administration in rabbits. <i>Journal of Surgical Research</i> , 2014, 187, 101-106.	0.8	5
46	Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model. <i>Gynecologic Oncology</i> , 2014, 133, 607-615.	0.6	16
47	Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 133, 346-352.	0.6	34
48	Ovarian cancer stem cells: Working towards the root of stemness. <i>Cancer Letters</i> , 2013, 338, 147-157.	3.2	122
49	No REST for fibroids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1980-1981.	3.3	1
50	Inhibition of gamma-secretase activity in combination with paclitaxel to reduce platinum-resistant ovarian tumor growth.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5578-5578.	0.8	0
51	Targeting the PI3K signaling cascade in <i>PIK3CA</i> mutated endometrial cancer in a primary human xenograft model.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13564-e13564.	0.8	0
52	Effect of sunitinib on functional reproductive outcome in a rabbit model. <i>Fertility and Sterility</i> , 2012, 98, 496-502.	0.5	3
53	Sunitinib reduces recurrent pelvic adhesions in a rabbit model. <i>Journal of Surgical Research</i> , 2012, 178, 860-865.	0.8	5
54	Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 3197-3206.	3.2	60

#	ARTICLE	IF	CITATIONS
55	Ovarian cancer stem cell markers: Prognostic and therapeutic implications. <i>Cancer Letters</i> , 2012, 322, 1-7.	3.2	148
56	Prolonging the female reproductive lifespan and improving egg quality with dietary omega-3 fatty acids. <i>Aging Cell</i> , 2012, 11, 1046-1054.	3.0	86
57	Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin. <i>PLoS ONE</i> , 2012, 7, e41593.	1.1	45
58	Dendritic cells in the circulation of women with preeclampsia demonstrate a pro-inflammatory bias secondary to dysregulation of TLR receptors. <i>Journal of Reproductive Immunology</i> , 2012, 94, 210-215.	0.8	38
59	Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome. <i>PLoS ONE</i> , 2012, 7, e30996.	1.1	32
60	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18708-18713.	3.3	381
61	Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 368.	3.0	49
62	Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer. <i>PLoS ONE</i> , 2011, 6, e18202.	1.1	35
63	Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. <i>Gynecologic Oncology</i> , 2011, 121, 212-217.	0.6	61
64	<i>cables1</i> is required for embryonic neural development: molecular, cellular, and behavioral evidence from the zebrafish. <i>Molecular Reproduction and Development</i> , 2011, 78, 22-32.	1.0	9
65	Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation. <i>Journal of Ovarian Research</i> , 2011, 4, 8.	1.3	15
66	Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model. <i>PLoS ONE</i> , 2011, 6, e28077.	1.1	62
67	Defining the Antagonistic Role of Omega-3 Polyunsaturated Fatty Acid in the Establishment and Early Maintenance of Endometriosis-Like Lesions in a Murine Model. <i>Biology of Reproduction</i> , 2011, 85, 379-379.	1.2	0
68	Correlates of the preoperative level of CA125 at presentation of ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 462-468.	0.6	28
69	<i>Cables1</i> protects p63 from proteasomal degradation to ensure deletion of cells after genotoxic stress. <i>EMBO Reports</i> , 2010, 11, 633-639.	2.0	22
70	Mouse models of uterine corpus tumors clinical significance and utility. <i>Frontiers in Bioscience - Elite</i> , 2010, E2, 882-905.	0.9	13
71	BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian Carcinoma. <i>Cancer Research</i> , 2010, 70, 7155-7165.	0.4	46
72	Surgical Debulking Before or After Chemotherapy: Stemming the Tide on Ovarian Cancer Recurrence. <i>Onkologie</i> , 2010, 33, 286-287.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Prostaglandin F2 β Represses IGF-I-Stimulated IRS1/Phosphatidylinositol-3-Kinase/AKT Signaling in the Corpus Luteum: Role of ERK and P70 Ribosomal S6 Kinase. <i>Molecular Endocrinology</i> , 2010, 24, 632-643.	3.7	33
74	Ultra-rapid vitrification of mouse oocytes in low cryoprotectant concentrations. <i>Reproductive BioMedicine Online</i> , 2010, 20, 201-208.	1.1	49
75	Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. <i>Reproductive Biology and Endocrinology</i> , 2010, 8, 147.	1.4	48
76	Cytokeratin 18 expression inhibits cytokine-induced death of cervical cancer cells. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1474-81.	1.2	10
77	Evidence for Cancer Stem Cells in Human Endometrial Carcinoma. <i>Cancer Research</i> , 2009, 69, 8241-8248.	0.4	111
78	HIF α 1 β and HIF α 2 β have divergent roles in colon cancer. <i>International Journal of Cancer</i> , 2009, 124, 763-771.	2.3	151
79	CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer. <i>Stem Cells</i> , 2009, 27, 2875-2883.	1.4	386
80	Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. <i>Breast Cancer Research</i> , 2009, 11, R36.	2.2	138
81	Constitutive Activation of Beta-Catenin in Uterine Stroma and Smooth Muscle Leads to the Development of Mesenchymal Tumors in Mice1. <i>Biology of Reproduction</i> , 2009, 81, 545-552.	1.2	129
82	The Current Status of Evidence for and Against Postnatal Oogenesis in Mammals: A Case of Ovarian Optimism Versus Pessimism?1. <i>Biology of Reproduction</i> , 2009, 80, 2-12.	1.2	101
83	Upregulation of MUC4 in Cervical Squamous Cell Carcinoma: Pathologic Significance. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 127-133.	0.9	20
84	Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. <i>International Journal of Cancer</i> , 2008, 123, 2782-2790.	2.3	86
85	Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2008, 110, 293-298.	0.6	53
86	Decreased survival in EGFR gene amplified vulvar carcinoma. <i>Gynecologic Oncology</i> , 2008, 111, 289-297.	0.6	55
87	Ablation of Leptin Signaling Disrupts the Establishment, Development, and Maintenance of Endometriosis-Like Lesions in a Murine Model. <i>Endocrinology</i> , 2008, 149, 506-514.	1.4	52
88	Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. <i>Cancer Biology and Therapy</i> , 2008, 7, 180-188.	1.5	16
89	Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. <i>Cell Cycle</i> , 2008, 7, 242-249.	1.3	94
90	Prostaglandin F2 β Stimulates the Expression and Secretion of Transforming Growth Factor B1 Via Induction of the Early Growth Response 1 Gene (EGR1) in the Bovine Corpus Luteum. <i>Molecular Endocrinology</i> , 2008, 22, 403-414.	3.7	70

#	ARTICLE	IF	CITATIONS
91	Acid sphingomyelinase involvement in tumor necrosis factor α -regulated vascular and steroid disruption during luteolysis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7670-7675.	3.3	29
92	Stem Cell Contribution to Ovarian Development, Function, and Disease. Endocrinology, 2008, 149, 4307-4311.	1.4	34
93	Cables 1 Mediates Progesterone-Induced Inhibition of Endometrial Epithelial Cell Proliferation.. Biology of Reproduction, 2008, 78, 129-129.	1.2	0
94	Loss of CABLES1, a Cyclin-dependent Kinase-interacting Protein that Inhibits Cell Cycle Progression, Results in Germline Expansion at the Expense of Oocyte Quality in Adult Female Mice. Cell Cycle, 2007, 6, 2678-2684.	1.3	24
95	The Cables Gene on Chromosome 18q Is Silenced by Promoter Hypermethylation and Allelic Loss in Human Colorectal Cancer. American Journal of Pathology, 2007, 171, 1509-1519.	1.9	30
96	Leptin Signaling Promotes the Growth of Mammary Tumors and Increases the Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor Type Two (VEGF-R2). Journal of Biological Chemistry, 2006, 281, 26320-26328.	1.6	216
97	Induction of interleukin-8 preserves the angiogenic response in HIF-1 α -deficient colon cancer cells. Nature Medicine, 2005, 11, 992-997.	15.2	394
98	Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 111-116.	3.3	85
99	Cooperative Expression of Monocyte Chemoattractant Protein 1 Within the Bovine Corpus Luteum: Evidence of Immune Cell-Endothelial Cell Interactions in a Coculture System1. Biology of Reproduction, 2005, 72, 1169-1176.	1.2	39
100	Increased growth rate, Delayed senescence and decreased serum dependence characterize cables-deficient cells. Cancer Biology and Therapy, 2005, 4, 654-658.	1.5	16
101	Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo. Cancer Biology and Therapy, 2005, 4, 110-114.	1.5	15
102	Loss of Cables, a Cyclin-Dependent Kinase Regulatory Protein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer. Cancer Research, 2004, 64, 202-208.	0.4	72
103	Loss of Cables, a Novel Gene on Chromosome 18q, in Ovarian Cancer. Modern Pathology, 2003, 16, 863-868.	2.9	21
104	Prostaglandin F $_{2\alpha}$ - and FAS-activating antibody-induced regression of the corpus luteum involves caspase-8 and is defective in caspase-3 deficient mice. Reproductive Biology and Endocrinology, 2003, 1, 15.	1.4	33
105	Signaling mechanisms in tumor necrosis factor alpha-induced death of microvascular endothelial cells of the corpus luteum. Reproductive Biology and Endocrinology, 2003, 1, 17.	1.4	58
106	Mutant mouse models and their contribution to our knowledge of corpus luteum development, function and regression. Reproductive Biology and Endocrinology, 2003, 1, 87.	1.4	8
107	Microvascular endothelial cells of the corpus luteum. Reproductive Biology and Endocrinology, 2003, 1, 89.	1.4	92
108	CD95 Rapidly Clusters in Cells of Diverse Origins. Cancer Biology and Therapy, 2003, 2, 392-395.	1.5	56

#	ARTICLE	IF	CITATIONS
109	Caspase-3 Is a Pivotal Mediator of Apoptosis during Regression of the Ovarian Corpus Luteum. <i>Endocrinology</i> , 2002, 143, 1495-1501.	1.4	112
110	The corpus luteum: an ovarian structure with maternal instincts and suicidal tendencies. <i>Frontiers in Bioscience - Landmark</i> , 2002, 7, d1949.	3.0	159
111	Endometrial Cancer in Women 40 Years Old or Younger. <i>Gynecologic Oncology</i> , 2001, 83, 388-393.	0.6	209
112	Caspase-3 Gene Knockout Defines Cell Lineage Specificity for Programmed Cell Death Signaling in the Ovary*. <i>Endocrinology</i> , 2001, 142, 2468-2480.	1.4	156
113	Putative Role of the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in the Survival of Granulosa Cells. <i>Endocrine</i> , 2000, 12, 315-321.	2.2	46
114	Decreased Progesterone Levels and Progesterone Receptor Antagonists Promote Apoptotic Cell Death in Bovine Luteal Cells. <i>Biology of Reproduction</i> , 2000, 62, 269-276.	1.2	112
115	Stress-induced mitogen-activated protein kinase signaling in the corpus luteum. <i>Molecular and Cellular Endocrinology</i> , 2000, 164, 59-67.	1.6	21
116	Characterization and Regulation of Type A Endothelin Receptor Gene Expression in Bovine Luteal Cell Types. <i>Endocrinology</i> , 1999, 140, 2110-2116.	1.4	32
117	Ovine Prostaglandin F _{2α} Receptor: Steroid Influence on Steady-State Levels of Luteal mRNA. <i>Endocrine</i> , 1999, 10, 105-112.	2.2	4
118	Increased bax and Interleukin-1 ^β -Converting Enzyme Messenger Ribonucleic Acid Levels Coincide with Apoptosis in the Bovine Corpus Luteum during Structural Regression. <i>Biology of Reproduction</i> , 1997, 56, 186-193.	1.2	111